These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27000512)

  • 1. Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints.
    Goldsmith C; Price P; Cross T; Loughlin S; Cowley I; Plowman N
    Semin Radiat Oncol; 2016 Apr; 26(2):149-56. PubMed ID: 27000512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery.
    Hiniker SM; Modlin LA; Choi CY; Atalar B; Seiger K; Binkley MS; Harris JP; Liao YJ; Fischbein N; Wang L; Ho A; Lo A; Chang SD; Harsh GR; Gibbs IC; Hancock SL; Li G; Adler JR; Soltys SG
    Semin Radiat Oncol; 2016 Apr; 26(2):97-104. PubMed ID: 27000505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer.
    Taniguchi CM; Murphy JD; Eclov N; Atwood TF; Kielar KN; Christman-Skieller C; Mok E; Xing L; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1090-5. PubMed ID: 23273994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels.
    Xue J; Kubicek G; Patel A; Goldsmith B; Asbell SO; LaCouture TA
    Semin Radiat Oncol; 2016 Apr; 26(2):135-9. PubMed ID: 27000510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy.
    LaCouture TA; Xue J; Subedi G; Xu Q; Lee JT; Kubicek G; Asbell SO
    Semin Radiat Oncol; 2016 Apr; 26(2):157-64. PubMed ID: 27000513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esophageal Dose Tolerance in Patients Treated With Stereotactic Body Radiation Therapy.
    Nuyttens JJ; Moiseenko V; McLaughlin M; Jain S; Herbert S; Grimm J
    Semin Radiat Oncol; 2016 Apr; 26(2):120-8. PubMed ID: 27000508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: implications for radiation dose escalation in carcinoma of the pancreas.
    Singh AK; Tierney RM; Low DA; Parikh PJ; Myerson RJ; Deasy JO; Wu CS; Pereira GC; Wahab SH; Mutic S; Grigsby PW; Hope AJ
    Radiat Oncol; 2006 Sep; 1():33. PubMed ID: 16952315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord.
    Grimm J; Sahgal A; Soltys SG; Luxton G; Patel A; Herbert S; Xue J; Ma L; Yorke E; Adler JR; Gibbs IC
    Semin Radiat Oncol; 2016 Apr; 26(2):165-71. PubMed ID: 27000514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction and Clinical Overview of the DVH Risk Map.
    Asbell SO; Grimm J; Xue J; Chew MS; LaCouture TA
    Semin Radiat Oncol; 2016 Apr; 26(2):89-96. PubMed ID: 27000504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Prediction Model for Duodenum Sparing With a Biodegradable Hydrogel Spacer for Pancreatic Cancer Radiation Therapy.
    Feng Z; Rao AD; Cheng Z; Shin EJ; Moore J; Su L; Kim SH; Wong J; Narang A; Herman JM; McNutt T; Li D; Ding K
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):651-659. PubMed ID: 30031143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
    Verma V; Lazenby AJ; Zheng D; Bhirud AR; Ly QP; Are C; Sasson AR; Lin C
    Radiother Oncol; 2017 Mar; 122(3):464-469. PubMed ID: 28089484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer.
    Murphy JD; Christman-Skieller C; Kim J; Dieterich S; Chang DT; Koong AC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1420-6. PubMed ID: 20399033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy.
    Kimsey F; McKay J; Gefter J; Milano MT; Moiseenko V; Grimm J; Berg R
    Semin Radiat Oncol; 2016 Apr; 26(2):129-34. PubMed ID: 27000509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
    Kelly P; Das P; Pinnix CC; Beddar S; Briere T; Pham M; Krishnan S; Delclos ME; Crane CH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e143-9. PubMed ID: 23200173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study.
    Qing SW; Ju XP; Cao YS; Zhang HJ
    Radiat Oncol; 2017 Jan; 12(1):6. PubMed ID: 28069017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
    Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
    Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy.
    Broggi S; Passoni P; Tiberio P; Cicchetti A; Cattaneo GM; Longobardi B; Mori M; Reni M; Slim N; Del Vecchio A; Di Muzio NG; Fiorino C
    Front Oncol; 2022; 12():983984. PubMed ID: 36761419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies.
    Bae SH; Kim MS; Cho CK; Kang JK; Lee SY; Lee KN; Lee DH; Han CJ; Yang KY; Kim SB
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e469-74. PubMed ID: 23078899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling.
    Duijm M; Tekatli H; Oomen-de Hoop E; Verbakel W; Schillemans W; Slotman BJ; Senan S; Nuyttens JJ
    Radiother Oncol; 2018 May; 127(2):233-238. PubMed ID: 29478763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma.
    Cattaneo GM; Passoni P; Longobardi B; Slim N; Reni M; Cereda S; di Muzio N; Calandrino R
    Radiother Oncol; 2013 Jul; 108(1):66-71. PubMed ID: 23726116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.